The CTC offices are currently closed for refurbishment. Access to trial TMFs and patient records will be limited during this period. We will still be able to receive post during this time, but there may be a small delay in responding to this. Our fax lines may also be subject to disruption. Where possible, please direct all correspondence via email to trial-specific email addresses. We appreciate your patience and understanding.

Due to COVID-19 and current government guidance, UCL CTC staff continue to work remotely with limited access to the office. Please continue to email the trial specific mailbox with any urgent queries. For paper CRF trials, please continue to copy and scan CRFs to the trial inboxes (remove all patient identifiers except Trial Number and Initials) until further notice.

 
Trial Details
Trial status:
Active (recruiting)
Recruitment start date:
Funder:
Sponsor:
UCL
Chief Investigator:
David Cunnningham
Recruitment target:
N/A
EudraCT number:
N/A
Contact details:
ctc.bnli@ucl.acuk
Lay summary:
RETRO-CHOP
A retrospective translational study: Characterisation of molecular predictors of outcome in patients with diffuse large B cell lymphoma treated on the R-CHOP14 vs 21 multicentre trial
Description
Design: This is a retrospective study which aims to perform biomarker analyses on archived samples from patients with diffuse large B cell lymphoma (DLBCL) who have been treated on the R-CHOP 14 vs 21 multicentre trial. This will include all trial patients who have donated their tissue for research purpose and have tumour tissue available. This study will evaluate the incidence and the predictive/prognostic value of several biomarkers and will provide a valuable platform to complement ongoing translational studies on the R-CHOP14 vs 21 study cohort. Assessment of DNA methylation and mutations are currently the main focus of this study, but other biomarkers (e.g. DNA copy number changes, gene expression profiling and metabolites may be considered for analysis).  
Treatment: Tissue samples from patients enrolled on the R-CHOP 14 vs 21 multicentre trial between 2005 and 2009 were collected and stored at the Haematological Malignancy Diagnostic Service (HMDS) of St James’ University Hospital, Leeds for biomarker analyses. Suitable samples will be sent to the Royal Marsden NHS Foundation Trust for the purpose of this study. Molecular analyses include, but are not limited to, DNA methylation analyses, DNA sequencing, RNA expression analyses and immunohistochemistry. The molecular analyses data will be collected in an anonymised fashion and correlated to clinical outcome data.
Key inclusion/exclusion criteria: DLBCL patients treated on the R-CHOP 14 vs 21 trial who consented for surplus tissue to be used in future ethically approved research.
Duration of recruitment: N/A
Aim
To evaluate the prognostic value of tumour biomarkers in patients with DLBCL treated on the R-CHOP 14 vs 21 multicentre trial.
Trial protocols
Trial protocols must not be applied to patients treated outside trials. UCL CTC can only ensure that approved trial investigators are provided with amendments to protocols.
No protocols have been currently made available for download
Trial documents
No documents have been currently made available for download
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2021 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us